NCT07667868

Brief Summary

The purpose of this study is to find out if BP2202 is safe and can treat participants with Relapsed/Refractory Multiple Myeloma.

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
18

participants targeted

Target at P25-P50 for phase_1

Timeline
27mo left

Started Oct 2026

Typical duration for phase_1

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 19, 2026

Completed
6 days until next milestone

First Posted

Study publicly available on registry

June 25, 2026

Completed
3 months until next milestone

Study Start

First participant enrolled

October 1, 2026

Completed
1.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2027

Expected
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2028

Last Updated

August 21, 2026

Status Verified

August 1, 2026

Enrollment Period

1.2 years

First QC Date

June 19, 2026

Last Update Submit

August 19, 2026

Conditions

Relapsed/Refractory Multiple Myeloma (RRMM)

Outcome Measures

Primary Outcomes (2)

  • Incidence of dose-limiting toxicities (DLTs; Part A)

    Number of participants who experienced a DLT. DLTs include specifically defined adverse events (AEs) considered to be related to BP2202

    Up to 6 weeks

  • Incidence of adverse events (AEs; Parts A and B)

    Number of participants who experienced AEs, adverse events of special interest (AESIs), or serious adverse events (SAEs)

    Up to approximately 2 years

Secondary Outcomes (3)

  • Overall Response Rate (Parts A and B)

    Up to approximately 2 years

  • Duration of Response (DoR) (Parts A and B)

    Up to approximately 2 years

  • Disease Control Rate (DCR) (Parts A and B)

    Up to approximately 2 years

Study Arms (1)

BP2202

EXPERIMENTAL
Biological: BP2202

Interventions

BP2202BIOLOGICAL

Intravenous infusion

BP2202

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Diagnosis of Multiple Myeloma with relapsed or refractory disease.
  • Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1
  • Adequate organ function.
  • Have measurable disease

You may not qualify if:

  • Known active central nervous system (CNS) involvement or exhibits clinical signs of meningeal involvement of Multiple Myeloma.
  • Known second malignancy that is progressing or requires active treatment or may interfere with study endpoints.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Multiple Myeloma

Condition Hierarchy (Ancestors)

Neoplasms, Plasma CellNeoplasms by Histologic TypeNeoplasmsHemostatic DisordersVascular DiseasesCardiovascular DiseasesParaproteinemiasBlood Protein DisordersHematologic DiseasesHemic and Lymphatic DiseasesHemorrhagic DisordersLymphoproliferative DisordersImmunoproliferative DisordersImmune System Diseases

Central Study Contacts

BP2202 Study team

CONTACT

+81358407679bp2202-001@brightpathbio.com

Director

CONTACT

zhang_l@brightpathbio.com

Study Design

Study Type
interventional
Phase
phase 1
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 19, 2026

First Posted

June 25, 2026

Study Start

October 1, 2026

Primary Completion (Estimated)

December 31, 2027

Study Completion (Estimated)

December 31, 2028

Last Updated

August 21, 2026

Record last verified: 2026-08

Data Sharing

IPD Sharing
Will not share